Mechanistically, PTPRD/PTPRT mutations are strongly associated with high TMB, high MSI score, and an enhanced anti-tumor microenvironment, thus PTPRD/PTPRT mutations may be a promising biomarker for the prediction of the ICI treatment response in several cancers. This evidence concerns the gene PTPRT and neoplasm.